11Apr/14

Gilead's Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C … – Stockhouse


Bidness Etc

Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C
Stockhouse
Study GS-US-334-0126 (Poster #1232), was a single-arm open-label Phase 2 trial in which patients with established recurrent HCV infection following liver transplantation received up to 24 weeks of therapy with Sovaldi plus RBV (escalating doses
Gilead’s Sovaldi Shows Efficacy & Safety In Chronic Hepatitis C PatientsNASDAQ
Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic The Herald | HeraldOnline.com (press release)

all 77 news articles »

10Apr/14

ProMetic's PBI-4050 Delivers New Positive Preclinical Results in Liver … – SYS-CON Media (press release)

ProMetic’s PBI-4050 Delivers New Positive Preclinical Results in Liver
SYS-CON Media (press release)
Liver transplantation is the only treatment available for patients with advanced stage of fibrosis. About ProMetic Life Sciences Inc. ProMetic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally

and more »

10Apr/14

Gilead Announces Results from Study of Sovaldi ® for Retreatment of Chronic … – Business Wire (press release)

Gilead Announces Results from Study of Sovaldi ® for Retreatment of Chronic
Business Wire (press release)
Efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection. Treatment response varies